Expert Analysis

Expert Analysis: Chronic Myeloid Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Expert Analysis: Chronic Myeloid Leukemia

Program Director: Roy A. Beveridge, MD

Faculty:

Brian Druker, MD
Charles L. Sawyers, MD
Moshe Talpaz, MD

Moderator: Allen S. Yang, MD, PhD

CME CREDIT INFORMATION

Release Date: 02/28/08

Expiration Date: 02/27/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite recent data using second-generation tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia who are resistant to imatinib
Discuss the potential role of second-generation tyrosine kinase inhibitors in the frontline treatment of chronic myeloid leukemia
Describe results with new molecular targeting agents undergoing evaluation in chronic myeloid leukemia
Summarize the importance of the mutational status in the management of patients chronic myeloid leukemia
Recall data on long-term outcomes in patients with chronic myeloid leukemia treated with imatinib

Topics covered include:

IRIS: Imatinib Treatment in Chronic Myeloid Leukemia at 6 Years
IRIS: Time to Complete Cytogenetic Response and Long-term Outcomes of Imatinib Therapy
Dasatinib in the Setting of Imatinib-Resistant Chronic-Phase CML (START-C and START-R Studies)
BCR-ABL Mutants and Response to Dasatinib in Chronic-Phase CML (START-C Substudy)
Nilotinib in Chronic-Phase CML With Imatinib Resistance or Intolerance
Dasatinib and Nilotinib in Newly Diagnosed Early Chronic-Phase CML
Effect of Previous Imatinib on Outcomes After Hematopoietic Stem Cell Transplantation in Patients With CML
Novel CML Agents: Bosutinib and INNO-406
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.